| Literature DB >> 34746306 |
Petr Stepka1, Monika Kratochvilova1, Michaela Kuchynka2,3, Martina Raudenska1, Hana Holcova Polanska1,4, Tomas Vicar1,5, Tomas Vaculovic2,6, Marketa Vaculovicova7,8, Michal Masarik1,4,7.
Abstract
The main dose-limiting side effect of cisplatin is nephrotoxicity. The utilization of cisplatin is an issue of balancing tumour toxicity versus platinum-induced nephrotoxicity. In this study, we focused on intraorgan distribution of common essential trace elements zinc, copper, and iron in healthy mouse kidneys and distribution of platinum after cisplatin treatment. Renal distribution in 12 nontreated Nu-Nu mice (males) was assessed by laser ablation inductively coupled plasma mass spectrometry (LA-ICP-MS). Furthermore, 9 Nu-Nu mice were treated with cisplatin. The order of elements concentration in kidneys was as follows: Fe > Zn > Cu. All three metals showed the higher concentrations at the cortex and medulla (28.60, 3.35, and 93.83 μg/g for Zn, Cu, and Fe, respectively) and lower concentration at the pelvis and the urinary tract (20.20, 1.93, and 62.48 μg/g for Zn, Cu, and Fe, respectively). No statistically significant difference between cortex and medulla was observed for these elements. After platinum treatment, the concentration of platinum in kidneys was enhanced more than 60-times, p < 0.001. Platinum significantly showed the highest accumulation in cortex (2.11 μg/g) with a gradient distribution. Platinum was less accumulated in medulla and pelvis than in cortex, and the lowest accumulation occurred in the urinary tract (1.13 μg/g). Image processing has been successfully utilized to colocalize metal distribution using LA-ICP-MS and histological samples images.Entities:
Mesh:
Substances:
Year: 2021 PMID: 34746306 PMCID: PMC8564192 DOI: 10.1155/2021/6800294
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
Figure 1Distribution of Fe, Zn, and Cu in kidney. (a) Distribution of metals in mineralised (decomposed) regions of kidney, (b) metal distribution maps obtained using LA-ICP-MS, and light microscopy image of a representative sample.
Figure 2Platinum distribution in kidneys of mouse untreated or treated with cisplatin. (a) Concentration of Pt in mineralized (decomposed) kidney samples before and after treatment with cisplatin. (b) Distribution of Pt in histological and mineralised regions of kidney, (c) metal distribution maps obtained using LA-IC/-MS and light microscopy image of a representative sample.
Summarization of Pt/Cu, Pt/Zn, and Zn/Cu median concentration ratios in homogenized and mineralized kidney samples and concentration range found using LA-ICP-MS (in parenthesis).
| Treatment | Pt/Cu | Pt/Zn | Zn/Cu |
|---|---|---|---|
| Nonreceiving PC-3 and nontreated with cisplatin | — | — | 7 (5-20) |
| Nonreceiving PC-3 and treated with cisplatin | 0.6 (0.25-2) | 0.2 (0.08-0.4) | 4 (2-18) |
| Receiving PC-3 and nontreated with cisplatin | — | — | 1 (4-20) |
| Receiving PC-3 and treated with cisplatin | 0.9 (0.4-4) | 0.2 (0.05-0.5) | 7 (3-13) |